Provided by Tiger Fintech (Singapore) Pte. Ltd.

Iterum Therapeutics Plc

1.45
+0.02001.40%
Volume:225.44K
Turnover:324.68K
Market Cap:50.14M
PE:-1.15
High:1.47
Open:1.47
Low:1.41
Close:1.43
Loading ...

Iterum Therapeutics PLC reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Iterum Therapeutics Q3 2024 Adj. EPS $(0.24) Misses $(0.20) Estimate. Cash And Equivalents Of $14.5M

Benzinga
·
14 Nov 2024

Iterum Therapeutics Q3 Adjusted Net Income USD -4.837 Million

THOMSON REUTERS
·
14 Nov 2024

Iterum Therapeutics Q3 Operating Income USD -4.887 Million

THOMSON REUTERS
·
14 Nov 2024

Iterum Therapeutics Q3 Operating Expenses USD -4.887 Million

THOMSON REUTERS
·
14 Nov 2024

Iterum Therapeutics Q3 Net Income USD -6.094 Million

THOMSON REUTERS
·
14 Nov 2024

Iterum Therapeutics PLC expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
12 Nov 2024

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

GlobeNewswire
·
11 Nov 2024

BRIEF-Iterum Therapeutics defers milestone payment to Pfizer

Reuters
·
02 Nov 2024

Iterum Therapeutics- Notified Pfizer, Electing to Defer Milestone Payment for 2 Years for Orlynvah, or Until Oct 25, 2026, Delivered Note to Pfizer

THOMSON REUTERS
·
02 Nov 2024

Iterum Therapeutics (ITRM) Receives a Buy from Maxim Group

TIPRANKS
·
29 Oct 2024

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships

Benzinga
·
28 Oct 2024

Iterum Therapeutics Plc : Maxim Group Raises Target Price to $10 From $7

THOMSON REUTERS
·
28 Oct 2024

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

PR Newswire
·
28 Oct 2024

Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs

seekingalpha
·
26 Oct 2024

BRIEF-Iterum Therapeutics To Renew Efforts For Strategic Transaction Involving ORLYNVAH

Reuters
·
26 Oct 2024